EG25614A - Novel pyrroles derivatives as pharmaceutical agents - Google Patents

Novel pyrroles derivatives as pharmaceutical agents

Info

Publication number
EG25614A
EG25614A EG2002050542A EG2002050542A EG25614A EG 25614 A EG25614 A EG 25614A EG 2002050542 A EG2002050542 A EG 2002050542A EG 2002050542 A EG2002050542 A EG 2002050542A EG 25614 A EG25614 A EG 25614A
Authority
EG
Egypt
Prior art keywords
pharmaceutical agents
derivatives
novel
novel pyrroles
pyrroles derivatives
Prior art date
Application number
EG2002050542A
Other languages
English (en)
Inventor
Jason Scott Sawyer
Hong-Yu Li
Douglas Wade Beight
Liao Junkai
Paola Ciapetti
William Thomas Mcmillen
Todd Vincent Decollo
Shawn Christopher Miller
Alexander Glenn Godfrey
Nicolas Anthony Mort
Theodore Goodson Jr
Jonathan Michael Yingling
David Kent Herron
Edward C R Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of EG25614A publication Critical patent/EG25614A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
EG2002050542A 2001-05-24 2002-05-22 Novel pyrroles derivatives as pharmaceutical agents EG25614A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29346401P 2001-05-24 2001-05-24

Publications (1)

Publication Number Publication Date
EG25614A true EG25614A (en) 2012-03-22

Family

ID=23129192

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2002050542A EG25614A (en) 2001-05-24 2002-05-22 Novel pyrroles derivatives as pharmaceutical agents

Country Status (37)

Country Link
US (1) US7087626B2 (de)
EP (1) EP1397364B1 (de)
JP (2) JP4519407B2 (de)
KR (1) KR100861630B1 (de)
CN (2) CN1951939A (de)
AR (1) AR036034A1 (de)
AT (1) ATE368041T1 (de)
AU (1) AU2002339268B2 (de)
BR (1) BR0209939A (de)
CA (1) CA2446820C (de)
CO (1) CO5540282A2 (de)
CY (1) CY1106871T1 (de)
CZ (1) CZ303808B6 (de)
DE (1) DE60221392T2 (de)
DK (1) DK1397364T3 (de)
DZ (1) DZ3506A1 (de)
EA (1) EA007782B1 (de)
EC (1) ECSP034859A (de)
EG (1) EG25614A (de)
ES (1) ES2289116T3 (de)
HR (1) HRP20030961B1 (de)
HU (1) HU228844B1 (de)
IL (2) IL158512A0 (de)
MX (1) MXPA03010630A (de)
MY (1) MY134586A (de)
NO (1) NO326701B1 (de)
NZ (1) NZ528525A (de)
PE (1) PE20030117A1 (de)
PL (1) PL221339B1 (de)
PT (1) PT1397364E (de)
SI (1) SI1397364T1 (de)
SK (1) SK287857B6 (de)
SV (1) SV2003001054A (de)
TW (1) TWI329644B (de)
UA (1) UA76461C2 (de)
WO (1) WO2002094833A1 (de)
ZA (1) ZA200308546B (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20030961B1 (en) * 2001-05-24 2012-01-31 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
AU2002357740A1 (en) * 2001-12-11 2003-06-23 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
EP1543001B1 (de) 2002-09-17 2007-08-15 Eli Lilly And Company Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
CA2506799A1 (en) * 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
UA80571C2 (en) * 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
WO2004048381A2 (en) * 2002-11-22 2004-06-10 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
EP1567527A1 (de) * 2002-11-27 2005-08-31 Eli Lilly And Company Kondensierte pyrazolderivate
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
US7511065B2 (en) * 2003-11-12 2009-03-31 Eli Lilly And Company Mixed lineage kinase modulators
EP1723146A1 (de) 2004-03-01 2006-11-22 Eli Lilly And Company Kondensierte pyrazolderivate als inhibitoren der tgf-beta-signalvermittlung zur behandlung von fibrose und neoplasmen
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
SG161217A1 (en) 2005-04-01 2010-05-27 Insa Rouen New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
RS53999B1 (sr) * 2005-07-22 2015-10-30 Eli Lilly And Company Piridin hinolin supstituisani pirolo [1,2-b] pirazol monohidrat kao tgf-beta inhibitor
US7608635B2 (en) 2005-08-12 2009-10-27 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
EP1973909A2 (de) * 2005-12-22 2008-10-01 Biogen Idec MA Inc. Modulatoren des transformierenden wachstumsfaktors
DE102005061840A1 (de) 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
EP2034995A2 (de) 2006-05-25 2009-03-18 Synta Pharmaceuticals Corporation Verfahren zur behandlung proliferativer erkrankungen in zusammenhang mit protoonkogenen produkten
EP2918288B1 (de) 2006-10-03 2017-08-16 Genzyme Corporation Verwendung von TGF-beta-Antagonisten zur Behandlung von Kleinkindern mit dem Risiko der Entwicklung von bronchopulmonaler Dysplasie
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR20100110815A (ko) 2007-12-12 2010-10-13 이 아이 듀폰 디 네모아 앤드 캄파니 살균제 이환식 피라졸
WO2010070060A1 (en) * 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
JP2012524073A (ja) * 2009-04-17 2012-10-11 スムマ ヘルス システムズ エルエルシー 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
AR081810A1 (es) * 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
EP2560640A1 (de) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer
EP2402337A1 (de) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridin-Verbindungen
EP2402340A1 (de) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridin-Verbindungen
EP2402338A1 (de) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridin-Verbindungen
EP2401915A1 (de) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridin-Verbindungen
EP2402339A1 (de) * 2010-06-29 2012-01-04 Basf Se Pyrazolopyridin-Verbindungen
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2012138945A1 (en) 2011-04-08 2012-10-11 Aestus Therapeutics, Inc. Methods of treating schizophrenia with pyrazole derivative inhibitors of tgf - beta
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
EP2780010A1 (de) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Kombinationstherapie aus hsp90-inhibitoren mit braf-inhibitoren
US9782452B2 (en) 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
CN116003600A (zh) 2012-10-05 2023-04-25 卡德门企业有限公司 人抗vegfr-2/kdr抗体
TWI443096B (zh) 2012-12-18 2014-07-01 Ind Tech Res Inst ３－（５－（４－（３－氟丙基）哌嗪－１－基）苯並咪唑－２－基）－１－氮雜薁－２－酮之單水合晶型及其製備方法與藥學組成物
CA2900300A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4
DK2970890T3 (da) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
US8975417B2 (en) * 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EP3527569B1 (de) 2014-02-03 2021-08-25 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridininhibitoren von ror-gamma zur behandlung von augentrockenheit
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
JO3336B1 (ar) 2014-10-07 2019-03-13 Lilly Co Eli مركبات أمينو بيريديلوكسي بيرازول
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016160881A1 (en) * 2015-04-01 2016-10-06 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
EP3313420B1 (de) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Verfahren und zusammensetzungen in bezug auf hämatopoetische stammzellenexpansion, -anreicherung und -pflege
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
EP3868750A1 (de) * 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulatoren von ror-gamma
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2017215506A1 (zh) * 2016-06-13 2017-12-21 南京明德新药研发股份有限公司 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
US11466003B2 (en) 2016-07-29 2022-10-11 Shanghai Yingli Pharmaceutical Co., Ltd Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
WO2018204661A1 (en) * 2017-05-05 2018-11-08 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
MA49685A (fr) 2017-07-24 2021-04-14 Vitae Pharmaceuticals Llc INHIBITEURS DE ROR gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
CR20200151A (es) 2017-10-11 2020-05-23 Hoffmann La Roche Compuestos bicíclicos y métodos de utilización de los mismos
JP2021035911A (ja) * 2017-11-15 2021-03-04 大日本住友製薬株式会社 縮環ピラゾール誘導体及びその医薬用途
PT3725786T (pt) * 2017-12-13 2023-10-17 Genfleet Therapeutics Shanghai Inc Forma cristalina e forma salina de inibidor de tgf-bri e método de preparação das mesmas
CN110066277B (zh) 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
CN110066276B (zh) 2018-01-24 2020-09-18 上海璎黎药业有限公司 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2019236766A1 (en) 2018-06-06 2019-12-12 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
WO2020019108A1 (en) 2018-07-23 2020-01-30 Guangzhou Othrotx Co., Ltd. Bisphosphonate drug conjugates
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
WO2020088526A1 (zh) * 2018-10-31 2020-05-07 南京明德新药研发有限公司 作为TGF-βR1激酶抑制剂的双环吡唑类化合物
EP3883556A2 (de) * 2018-11-22 2021-09-29 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Tgf-beta-inhibitor und prodrugs
ES2972516T3 (es) 2018-12-27 2024-06-13 Nexys Therapeutics Inc Derivados de (piridin-2-il)amina como inhibidores de TFG-BETA R1 (Alk5) para el tratamiento del cáncer
CA3124700A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
PH12021551324A1 (en) 2019-01-08 2022-04-25 Kyorin Seiyaku Kk 15-pgdh inhibitor
CN113316575B (zh) * 2019-01-24 2022-03-18 江苏奥赛康药业有限公司 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物
US12304897B2 (en) 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CN113557236B (zh) * 2019-06-10 2022-05-10 中国科学院广州生物医药与健康研究院 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
EP4087657A1 (de) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5-inhibitoren, konjugate und verwendungen davon
CN114867723B (zh) * 2020-07-23 2023-05-30 江苏奥赛康药业有限公司 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物
CN116249692B (zh) 2020-09-28 2024-08-23 四川科伦博泰生物医药股份有限公司 吡唑类化合物及其制备方法和用途
CN114437082B (zh) * 2020-11-06 2025-04-04 江苏先声药业有限公司 喹啉类化合物
CN115703750B (zh) * 2021-08-17 2024-07-02 黑龙江华瑞生物科技有限公司 一种1-氨基-4-甲基哌嗪的提取纯化方法
CN114249742B (zh) * 2021-11-22 2022-11-01 郑州大学 一种光气探针、荧光书写检测笔及其在光气检测中的应用
CN115969801B (zh) * 2023-03-21 2023-08-25 劲方医药科技(上海)有限公司 用于癌症的药物组合物及其制备方法
EP4727586A1 (de) 2023-06-13 2026-04-22 Synthis Therapeutics, Inc. Anti-cd5-antikörper und ihre verwendungen
GB202309553D0 (en) 2023-06-24 2023-08-09 Ucl Business Ltd Compostions and uses thereof
CN118652155B (zh) * 2024-06-17 2026-02-27 南京工业大学 一种二芳基乙炔的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
ES2130269T3 (es) * 1992-06-17 1999-07-01 Upjohn Co Oximas sustituidas con piridina, pirrolidina y azepina utiles como agentes contra la aterosclerosis y antihipercolesterolemicos.
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
ATE208199T1 (de) * 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
US5358947A (en) 1993-09-13 1994-10-25 American Cyanamid Company Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones
AUPN419395A0 (en) * 1995-07-17 1995-08-10 Treescope Development Co. Pty. Ltd. Plant protector
FR2746306B1 (fr) * 1996-03-22 1998-04-30 Oreal Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles ; leur utilisation pour la teinture comme coupleurs, procede de teinture
JP2002508754A (ja) 1997-05-22 2002-03-19 ジー ディ サール アンド カンパニ ｐ３８キナーゼ阻害剤としての置換基を有するピラゾール類
FR2772379B1 (fr) * 1997-12-16 2000-02-11 Oreal Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles; leur utilisation pour la teinture comme base d'oxydation, procede de teinture; nouveaux pyrazolo-azoles
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
EP1156045A4 (de) * 1999-01-28 2002-04-17 Nippon Shinyaku Co Ltd Amid-derivate und drogen-zusammensetzungen
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
ES2222919T3 (es) * 1999-08-27 2005-02-16 Abbott Laboratories Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2.
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
EP1326619A2 (de) * 2000-10-11 2003-07-16 Merck & Co., Inc. Pyrrolidin-modulatoren der ccr5-chemokin-rezeptor-aktivität
US20040087623A1 (en) 2001-02-02 2004-05-06 Gellibert Francoise Jeanne Pyrazole derivatives against tgf overexpression
HRP20030961B1 (en) * 2001-05-24 2012-01-31 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
MXPA05012869A (es) * 2003-05-28 2006-02-22 M & J Fibretech As Un metodo y un distribuidor de fibras para tendido al aire de fibras.
JP4882198B2 (ja) 2003-09-25 2012-02-22 日産自動車株式会社 燃料電池システム

Also Published As

Publication number Publication date
CZ20033128A3 (cs) 2004-06-16
HUP0400451A2 (hu) 2004-12-28
HU228844B1 (en) 2013-06-28
DZ3506A1 (fr) 2002-11-28
PL221339B1 (pl) 2016-03-31
EP1397364A1 (de) 2004-03-17
IL158512A (en) 2009-07-20
MXPA03010630A (es) 2004-03-09
EA007782B1 (ru) 2007-02-27
DE60221392D1 (de) 2007-09-06
SV2003001054A (es) 2003-03-18
WO2002094833A1 (en) 2002-11-28
EA200301289A1 (ru) 2004-06-24
CN1511157A (zh) 2004-07-07
HK1064375A1 (en) 2005-01-28
JP2004535404A (ja) 2004-11-25
ZA200308546B (en) 2005-04-26
CA2446820C (en) 2010-07-13
CO5540282A2 (es) 2005-07-29
SK287857B6 (sk) 2012-01-04
HRP20030961B1 (en) 2012-01-31
JP4519407B2 (ja) 2010-08-04
US20040106604A1 (en) 2004-06-03
NO20035193L (no) 2003-11-21
NO20035193D0 (no) 2003-11-21
DK1397364T3 (da) 2007-11-26
SK14162003A3 (en) 2004-11-03
NO326701B1 (no) 2009-02-02
TWI329644B (en) 2010-09-01
CN1269820C (zh) 2006-08-16
AU2002339268B2 (en) 2007-05-31
UA76461C2 (en) 2006-08-15
IL158512A0 (en) 2004-05-12
EP1397364B1 (de) 2007-07-25
CA2446820A1 (en) 2002-11-28
JP2009197016A (ja) 2009-09-03
US7087626B2 (en) 2006-08-08
CN1951939A (zh) 2007-04-25
ES2289116T3 (es) 2008-02-01
ECSP034859A (es) 2004-01-28
DE60221392T2 (de) 2008-04-17
BR0209939A (pt) 2004-03-30
SI1397364T1 (sl) 2007-12-31
PE20030117A1 (es) 2003-02-12
CY1106871T1 (el) 2012-09-26
HRP20030961A2 (en) 2005-08-31
KR100861630B1 (ko) 2008-10-07
PT1397364E (pt) 2007-10-22
CZ303808B6 (cs) 2013-05-09
KR20030097895A (ko) 2003-12-31
HUP0400451A3 (en) 2008-08-28
PL367199A1 (en) 2005-02-21
MY134586A (en) 2007-12-31
NZ528525A (en) 2005-10-28
ATE368041T1 (de) 2007-08-15
AR036034A1 (es) 2004-08-04

Similar Documents

Publication Publication Date Title
IL158512A0 (en) Novel pyrrole derivatives as pharmaceutical agents
EP1450824A4 (de) Pharmazeutische zusammensetzung
GB0111597D0 (en) Pharmaceutical compositions
HUP0303163A3 (en) Tramadol-based pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
GB0101227D0 (en) Pharmaceutical compounds
GB0129117D0 (en) Pharmaceutical composition
GB0101225D0 (en) Pharmaceutical compounds
GB0116107D0 (en) Pharmaceutical composition
GB0104752D0 (en) Pharmaceutical compositions
GB0026578D0 (en) Heterocyclic derivatives useful as pharmaceutical agents
GB0127805D0 (en) Pharmaceutical composition
PL370037A1 (en) Pharmaceutical composition
GB0129872D0 (en) Novel pharmaceutical
GB2382302B (en) Pharmaceutical compositions
IL157411A0 (en) Pharmaceutical composition
GB0130509D0 (en) Novel pharmaceutical
GB0130510D0 (en) Novel pharmaceutical
GB0129876D0 (en) Novel pharmaceutical
GB0130511D0 (en) Novel pharmaceutical
HU0103049D0 (en) Pharmaceutical composition
GB0125061D0 (en) Pharmaceutical composition
GB0126732D0 (en) Pharmaceutical compositions
GB0129871D0 (en) Novel pharmaceutical
GB0130957D0 (en) Pharmaceutical composition